Vincristin-Ronts injection for 1mg / ml 1 ml No. 1 bottle


More info

Vincristin-Ronts injection solution 1mg / ml 1ml No. 1 bottle

The solution for IV injection is clear, from colorless to light yellow.

1 ml
Vincristine sulfate 1 mg


mannitol - 100 mg, methyl parahydroxybenzoate - 1.8 mg, propyl parahydroxybenzoate - 0.2 mg, sodium hydroxide - to pH 4.5, sulfuric acid - to pH 4.5, water d / and - to 1 ml.
Clinico-pharmacological group: Antineoplastic drug

Pharmaco-therapeutic group:

Antitumor agent, alkaloid

pharmachologic effect

Antitumor agent. The mechanism of action is associated with the blockade of tubulin and the stop of cell division in metaphase.


Gets through the BBB in small quantities. Plasma protein binding is about 75%. Biotransforming in the liver. Excreted mainly in the form of metabolites, with bile (about 67%) and the kidneys (about 12%).


Acute leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, sarcomas of bones and soft tissue, osteosarcoma, neuroblastoma, Kaposi's sarcoma, uterine sarcoma, breast cancer, small cell lung cancer, melanoma, epithelioma, carcinoma of the renal pelvis and ureter , bladder cancer, Wilms tumor, cervical cancer, germ cell tumors of the testicles and ovaries, uterine choriocarcinoma, ependymoma, meningioma, pleurisy of tumor etiology, malignant tumors of the genital organs in girls. Idiopathic thrombocytopenic purpura (with resistance to corticosteroids and the ineffectiveness of splenectomy).

Dosing regimen

They establish individually, depending on the evidence and the stage of the disease, the state of the hematopoietic system, the scheme of antitumor therapy.

Side effect

On the part of the hematopoietic system: leukopenia, anemia, thrombocytopenia.
On the part of the central nervous system and peripheral nervous system: neuropathy, peripheral nerve neuritis, headache, convulsions, ataxia, depression, diplopia, ptosis, hallucinations, sleep disorders.
On the part of the urinary system: polyuria, dysuria, atony of the bladder, edema, acute urinary nephropathy.
On the part of the digestive system: vomiting, diarrhea, stomatitis, constipation, anorexia, paralytic ileus (especially often in children).
Other: alopecia (taking place after the cancellation of treatment), hypotension, edema.


Diseases of the central and peripheral nervous system, severe leukopenia, pregnancy.

Use during pregnancy and lactation

Vincristine is contraindicated for use during pregnancy. If necessary, use during lactation should stop breastfeeding.
Women of childbearing age who receive vincristine should use reliable contraceptive methods.
In experimental studies established teratogenic and embryotoxic effect of vincristine.

Use in elderly patients
The risk of neurotoxic effects is higher in elderly patients. With the development of peripheral neuritis should stop the introduction of vincristine.

special instructions

Do not recommend the use of vincristine in patients with chickenpox (including recently suffered or after contact with the sick), with herpes zoster, and other acute infectious diseases.
Caution must be exercised when using vincristine for gout (including in history) and nephrolithiasis, as well as in patients who have previously received cytotoxic or radiation therapy.
The frequency of side effects of vincristine is related to the total dose and duration of therapy.
With simultaneous radiotherapy to the area of ​​the spinal cord may increase the neurotoxic effect of vincristine.
The risk of neurotoxic effects is higher in elderly patients and those with neurological diseases in history. With the development of peripheral neuritis should stop the introduction of vincristine.
In the course of treatment, it is necessary to control the picture of peripheral blood, the activity of liver transaminases and LDH, the concentration of uric acid and bilirubin in the blood plasma.
During treatment, vaccination of patients and their families is not recommended.
With caution prescribed with simultaneous use of drugs that inhibit the CYP3A isoenzyme.
In experimental studies, the carcinogenic and mutagenic effects of vincristine have been established.

Drug interaction

With simultaneous use of vincristine enhances the neurotoxic effects of other drugs.
With simultaneous use of vincristine weakens the effect of arthritic drugs. With simultaneous use with uricosuric drugs increases the risk of nephropathy.
The introduction of vincristine before the use of bleomycin increases the antitumor effect of therapy.
Simultaneous use with mitomycin C can cause respiratory depression, bronchospasm, especially in predisposed patients.
With the simultaneous use of vincristine and itraconazole, an earlier and more severe development of the neurotoxic effect is possible.

It is a pharmaceutical drug. Use only as directed by your doctor.

Attention! During storage must comply with the temperature regime.